Risici forbundet med øgede doser af myelosuppressive lægemidler Behandling med filgrastim alene udelukker ikke trombocytopeni og anæmi fremkaldt af myelosuppressive lægemidler.
Risk associated with increased doses of myelosuppressive medicinal products Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products.